EA vs 22.2% stroke with medical
therapy at 5 years— but still statistically significant.3 Stenoses ⬍50% were not benefited by CEA.
2. CAS in symptomatic stenosis. A number of trials
have examined the role of CAS in the management of
neurologically symptomatic patients with ⬎50% diameter
stenosis. As previously mentioned, SAPPHIRE demonstrated overall equivalence of CAS and CEA